here's the deal though.. Until Mannkind puts a positive spin on their product and accomplishments, they can talk till they are blue in the face. For crying out loud, Matt Peffer may be an excellent CFO, he is STILL a HORRIBLE Public Relations guy.
Until Mannkind hires a SPIN doctor, no matter how many doctors want to prescribe, they shadow of Exubera and lung cancer will continue!!
I've been holding on to my shares and will continue to, but I am quite honestly disgusted by the lack of signs coming from the company. I know they are trying to be forthright, but for them not to defend their product is
Why? Simple -One year anniversary of the Adcom surprise!
Don't bother. Matt is a PUTZ.
I'd call Hakan. He seems to have more succinct answers.
don't get me wrong.. but Sanofi STILL needs to market. why would Mannkind give them sixty five percent if they are not going to market? that's what they were HIRED to do!
Today therapeutic insulin is delivered via injection under the skin (subcutaneous) or via an inhalation device. Therefore, it must be designed (formulated and engineered) in a manner that allows it to be stored externally, taken into the body and reach the bloodstream ready to mimic, as closely as possible, the physiologic action of native insulin.
So if you don't need the $$s now, the best thing to do is sit it out. Don't try to influence/encourage some of the posters (bashers) on this board. If the product is successful (and it will be); pps will take care of itself.
The fact of the matter is Afrezza is going to be hugely successful, and a paradigm shift takes a bit of time.
The reason, we cannot compare to Apple is because unlike a "shiny" new thing you can hold in your hand, Afrezza is a drug, that treats a disease, not a fashion statement. Hence, a lot of Endos, GPs and even
diabetics are taking a wait and see approach, which is understandable.
I challenge anyone to actually post a negative sentiment from one person who has actually used Afrezza and has decided that they want to go back to their injections!!
I am willing to bet most of the shorts are on MARGIN though. Hence the LOONG wait. They do not want to cover yet. Cramer, yes even Jim Cramer, said back in August, shorts will have to cover. Yes the numbers aren't parabolic right now, however, ANYONE who has actually used Afrezza absolutely LOVES it. When this catches fire, (and it's a WHEN) I honestly believe that there will be no stopping the Mannkind locomotive.
I agree PPS will creep up, however, I am having my doubts that it will be orderly. Too much at stake now.
hmmm.. what if.. just what if.. the script numbers spike this Friday?
what if, just what if...EXACTLY 1 year after ADCOM approval, a short has to finally cover their position because they get a margin call? After all, how long can they REALLY sustain paying significant interest?
what if, what if GS's downgrade was a buy signal to their cronies?
what if, what if SNY really does have 1/2 shares slated for a buyout of MNKD that they are allowed to exercise starting Friday?
things that make you go hmmmm
Lets see: 405M share float - 40% owned by Al Mann leaves about 244M shares.
91M/244M is about 38% short.
Cramer back in August 2014 said shorts would eventually have to cover. He said he thinks it is going to be a “Pyrrhic victory” for those betting against Mannkind.
My guess is that these shorts were trapped prior to Adcom, and that was the surprise for everyone.
Let's see Adcom happened when?? Exactly 1 year ago!
So I have a question for more saavy investors.. Any deadlines on how long someone can short?? I assume big player here.
One way investors can do their part! Email your local affiliate to request them to do a story on Inhaled insulin.. and viola! we'll see a lot of this ! I've emailed my affiliate!